» Articles » PMID: 24305035

Low Helicobacter Pylori Primary Resistance to Clarithromycin in Gastric Biopsy Specimens from Dyspeptic Patients of a City in the Interior of São Paulo, Brazil

Overview
Publisher Biomed Central
Specialty Gastroenterology
Date 2013 Dec 6
PMID 24305035
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Clarithromycin, amoxicillin, and a pump proton inhibitor are the most common drugs recommended as first-line triple therapy for H.pylori treatment, which results in eradication rates close to 80%, varying regionally, principally due to emergency cases and increases of clarithromycin resistant strains. Nucleotide substitutions at the H. pylori domain V of the 23S rRNA fraction are involved in the macrolide resistance and the A2142G and A2143G mutations are predominant in clinical isolates worldwide including in Brazil. As H. pylori culture is fastidious, we investigated the primary occurrence of H. pylori A2142G and A2143G rDNA 23S mutations using a molecular approach directly on gastric biopsies of dyspeptic patients consecutively attended at Hospital das Clinicas of Marilia, São Paulo, Brazil.

Methods: Biopsy specimens obtained from 1137 dyspeptic patients, were subjected to histopathology and H. pylori diagnosis by histology and PCR. PCR/RFLP assay was used to detect A2142G and A2143G point mutations at domain V of the H. pylori 23S rDNA associated with clarithromycin resistance. Through the developed assay, a 768 bp PCR amplicon corresponding to1728 to 2495 bp of the 23S H. pylori rDNA is restricted with MboII for A2142G mutation detection and with BsaI for A2143G mutation detection. Occurrence of 23S rDNA A2142G results in two DNA fragments (418 and 350 bp) and of 23S rDNA A2143G results in three DNA fragments (108, 310 and 350pb), due to a conserved BsaI restriction site.

Results: The PCR method used to diagnose H. pylori presented sensitivity, specificity and accuracy of 77,6%, 79,3% and 78,6%, respectively, compared to histology, the gold standard method for H. pylori diagnosis used in our routine. Prevalence of H.pylori with clarithromycin resistant genotypes was 2,46%, with predominance of A2143G 23S rDNA point mutation.

Conclusions: The PCR/RFLP assay was a rapid and accurate H.pylori diagnostic and clarithromycin resistance determination method useful for routine practice. As prevalence of primary resistance of H.pylori to clarithromycin due to A2142G and A2143G mutations remains low in Marilia, the standard clarithromycin containing triple therapy is still valid.

Citing Articles

Functional determination of site-mutations in involved in metronidazole resistance of .

Huang J, Li Z, Ge F, Sun C, Deng Z, Yao W Front Cell Dev Biol. 2024; 12:1435064.

PMID: 39100097 PMC: 11294100. DOI: 10.3389/fcell.2024.1435064.


Comparative Study of Helicobacter Pylori Resistance to Clarithromycin and Metronidazole and Its Association with Epidemiological Factors in A Moroccan Population.

Essaidi I, Bounder G, Jouimyi R, Boura H, Elyounsi I, Kheir F Asian Pac J Cancer Prev. 2022; 23(8):2755-2761.

PMID: 36037131 PMC: 9741911. DOI: 10.31557/APJCP.2022.23.8.2755.


Next-Generation Sequencing-Based Study of Isolates from Myanmar and Their Susceptibility to Antibiotics.

Subsomwong P, Doohan D, Fauzia K, Akada J, Matsumoto T, Yee T Microorganisms. 2022; 10(1).

PMID: 35056645 PMC: 8781859. DOI: 10.3390/microorganisms10010196.


The interplay between mutations in cagA, 23S rRNA, gyrA and drug resistance in Helicobacter pylori.

Vianna J, Ramis I, Ramos D, Gastal O, Silva R, Goncalves C Rev Inst Med Trop Sao Paulo. 2018; 60:e25.

PMID: 29972462 PMC: 6029892. DOI: 10.1590/s1678-9946201860025.


Clarithromycin-Based Triple Therapy is Still Useful as an Initial Treatment for Infection in the Dominican Republic.

Miftahussurur M, Cruz M, Subsomwong P, Jimenez Abreu J, Hosking C, Nagashima H Am J Trop Med Hyg. 2017; 96(5):1050-1059.

PMID: 28193745 PMC: 5417194. DOI: 10.4269/ajtmh.16-0729.


References
1.
Assumpcao M, Martins L, Barbosa H, Dos Santos Barile K, Almeida S, Assumpcao P . Helicobacter pylori in dental plaque and stomach of patients from Northern Brazil. World J Gastroenterol. 2010; 16(24):3033-9. PMC: 2890944. DOI: 10.3748/wjg.v16.i24.3033. View

2.
Sakinc T, Baars B, Wuppenhorst N, Kist M, Huebner J, Opferkuch W . Influence of a 23S ribosomal RNA mutation in Helicobacter pylori strains on the in vitro synergistic effect of clarithromycin and amoxicillin. BMC Res Notes. 2012; 5:603. PMC: 3522010. DOI: 10.1186/1756-0500-5-603. View

3.
Eisig J, Silva F, Barbuti R, Navarro-Rodriguez T, Moraes-Filho J, Pedrazzoli Jr J . Helicobacter pylori antibiotic resistance in Brazil: clarithromycin is still a good option. Arq Gastroenterol. 2011; 48(4):261-4. DOI: 10.1590/s0004-28032011000400008. View

4.
Fontana C, Favaro M, Minelli S, Criscuolo A, Pietroiusti A, Galante A . New site of modification of 23S rRNA associated with clarithromycin resistance of Helicobacter pylori clinical isolates. Antimicrob Agents Chemother. 2002; 46(12):3765-9. PMC: 132752. DOI: 10.1128/AAC.46.12.3765-3769.2002. View

5.
van Doorn L, Glupczynski Y, Kusters J, Megraud F, Midolo P, Queiroz D . Accurate prediction of macrolide resistance in Helicobacter pylori by a PCR line probe assay for detection of mutations in the 23S rRNA gene: multicenter validation study. Antimicrob Agents Chemother. 2001; 45(5):1500-4. PMC: 90495. DOI: 10.1128/AAC.45.5.1500-1504.2001. View